BioNTech SE logo

BNTX - BioNTech SE News Story

$168.95 7.2  4.4%

Last Trade - 22/04/21

Large Cap
Market Cap £28.06bn
Enterprise Value £27.10bn
Revenue £416.7m
Position in Universe 329th / 6852

New Zealand to buy enough Pfizer COVID-19 vaccines for entire population

Mon 8th March, 2021 3:01am
SYDNEY, March 8 (Reuters) - New Zealand will buy additional
COVID-19 vaccines, developed by Pfizer Inc  PFE.N  and Germany's
BioNTech  22UAy.DE , which will be enough to vaccinate the whole
country, Prime Minister Jacinda Ardern said on Monday.
    The government has signed an agreement to buy an extra 8.5
million doses, enough to vaccinate over 4 million people, Ardern
said, adding the vaccines were expected to reach the country in
the second half of the year.
    "This brings our total Pfizer order to 10 million doses or
enough for 5 million people to get the two shots needed to be
fully vaccinated against COVID-19," Ardern said in a statement.
    The government's original agreement with Pfizer was for 1.5
million doses, enough to vaccinate 750,000 people.*:nL4N2H30QG
    Ardern said the decision to make Pfizer the country's
primary vaccine provider was taken after it was shown to be
about 95% effective at preventing symptomatic infection. 
    New Zealand started its national rollout of the
Pfizer-BioNTech's COVID-19 vaccine last month and expects to
inoculate its entire population by the end of the year.
    With just over 2,000 confirmed COVID-19 cases and 26 deaths,
New Zealand largely contained the pandemic compared with other
developed countries, helped by speedy tracking systems, border
closures and snap lockdowns. 
    Auckland, New Zealand's biggest city, emerged on Sunday from
a strict week long lockdown imposed after a community cluster of
the more contagious British coronavirus variant.*:nL1N2L500X
    It reported no new cases on Monday.

 (Reporting by Renju Jose; Editing by Michael Perry)
 ((; +61 29171 7126;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.